Our research focuses on the development of gene therapies for diseases that affect the central nervous system. As of December, 2023, the FDA has approved AAV-based gene therapies for a handful of genetic stores, including spinal muscular atrophy,
Melden Sie sich an oder starten Sie Ihre kostenlose Testversion, um auf diese Inhalt zuzugreifen